Report Feature
The future of the global biologics market looks promising with opportunities in the oncology, immunological disorder, cardiovascular disorders, and hematological disorders. The global biologics market is expected to grow with a CAGR of XX% from 2020 to 2025. The major drivers for this market are rising biologics contract manufacturing services and recent advancements in biological science.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global biologics market report, please download the report brochure.
In this market, monoclonal antibodies is the largest product type of biologics, whereas microbial is the largest source. Growth in various segments of the biologics market are given below:
The study includes trends and forecast for the global biologics market by product, source, disease category, manufacturing, distribution channel, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
- Monoclonal Antibodies (mABs)
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others
By Source [Value ($ Million) shipment analysis for 2014 – 2025]:
- Microbial
- Mammalian
- Others
By Disease Category [Value ($ Million) shipment analysis for 2014 – 2025]:
- Oncology
- Immunological Disorder
- Cardiovascular Disorders
- Hematological Disorders
- Others
By Manufacturing [Value ($ Million) shipment analysis for 2014 – 2025]:
- Outsourced
- In-house
By Distribution Channel [Value ($ Million) shipment analysis for 2014 – 2025]:
- Online
- Offline
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
-
North America
- United States
- Canada
- Mexico
-
Europe
- United Kingdom
- Germany
- France
-
Asia Pacific
- China
- India
- Japan
-
The Rest of the World
- Brazil
Some of the biologics companies profiled in this report include Eli Lilly & Company, Samsung Biologics, F Hoffman La Roche, Celltrion, Addgene, Amgen, Abbvie, Sanofi, Pfizer, and Merck & Co.
Lucintel forecasts that the monoclonal antibodies (mABs) will remain the largest segment over the forecast period due to its increasing usage in different therapeutic areas such as cancer management, treatment of autoimmune diseases, including rheumatoid arthritis.
Within this market, microbial will remain the largest segment by source over the forecast period due to increasing number of drugs generated by using microbial system such as recombinant insulin, platelet-derived growth factor, granulocyte-macrophage colony-stimulating factor, and recombinant interferon.
North America will remain the largest region over the forecast period due to increasing R&D activities in biotechnology and presence of significant participants in this region.
|
Features of the Global Biologics Market |
|
|
This report answers following key questions |
|
Q.1 What are some of the most promising potential, high-growth opportunities for the global biologics market by product (monoclonal antibodies (mABs), vaccines, recombinant proteins, antisense, RNAi, & molecular therapy, and others), source (microbial, mammalian, and others), disease category (oncology, immunological disorder, cardiovascular disorders, hematological disorders, and others), manufacturing (outsourced and in-house), distribution channel (online and offline), and region (North America, Europe, Asia Pacific, and Rest of the World)? Q.2 Which segments will grow at a faster pace and why? Q.3 Which region will grow at a faster pace and why? Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global biologics market? Q.5 What are the business risks and threats to the global biologics market? Q.6 What are the emerging trends in this biologics market and the reasons behind them? Q.7 What are some changing demands of customers in this biologics market? Q.8 What are the new developments in this biologics market? Which companies are leading these developments? Q.9 Who are the major players in this biologics market? What strategic initiatives are being implemented by key players for business growth? Q.10 What are some of the competitive products and processes in this biologics market, and how big of a threat do they pose for loss of market share via material or product substitution? Q.11 What M&A activities did take place in the last five years in the global biologics market? |
Report Scope
| Key Features | Description |
| Base Year for Estimation | 2019 |
|
Trend Period (Actual Estimates) |
2014-2019 |
| Forecast Period | 2020-2025 |
| Pages | More than 150 |
| Market Representation / Units | Revenue in US $ Million |
| Report Coverage | Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling |
| Market Segments | Product (Monoclonal Antibodies (mABs), Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others), Source (Microbial, Mammalian, and Others), Disease Category (Oncology, Immunological Disorder, Cardiovascular Disorders, Hematological Disorders, and Others), Manufacturing (Outsourced and In-house), and Distribution Channel (Online, and Offline) |
Regional Scope |
North America (USA, Mexico, and Canada), Europe (United Kingdom, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil) |
| Customization | 10% Customization without Any Additional Cost |
Table of Contents
1. Executive Summary
7.2 Emerging Trends in the Global Biologics Market
4.1 Global Biologics Market by Region
4.2.1 Market by Product: Monoclonal Antibodies (mABs), Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others
4.2.2 Market by Source: Microbial, Mammalian, and Others
4.2.3 Market by Disease Category: Oncology, Immunological Disorder, Cardiovascular Disorders, Hematological Disorders, and Others
4.2.4 Market by Manufacturing: Outsourced and In-house
4.2.5 Market by Distribution Channel: Online and Offline
4.2.6 The United States Biologics Market
4.2.7 The Canadian Biologics Market
4.2.8 The Mexican Biologics Market
4.3.1 Market by Product: Monoclonal Antibodies (mABs), Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others
4.3.2 Market by Source: Microbial, Mammalian, and Others
4.3.3 Market by Disease Category: Oncology, Immunological Disorder, Cardiovascular Disorders, Hematological Disorders, and Others
4.3.4 Market by Manufacturing: Outsourced and In-house
4.3.5 Market by Distribution Channel: Online and Offline
4.3.6 The Biologics Market of United Kingdom
4.3.7 The Spanish Biologics Market
4.3.8 The German Biologics Market
4.3.9 The French Biologics Market
4.4.1 Market by Product: Monoclonal Antibodies (mABs), Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others
4.4.2 Market by Source: Microbial, Mammalian, and Others
4.4.3 Market by Disease Category: Oncology, Immunological Disorder, Cardiovascular Disorders, Hematological Disorders, and Others
4.4.4 Market by Manufacturing: Outsourced and In-house
4.4.5 Market by Distribution Channel: Online and Offline
4.4.6 The Chinese Biologics Market
4.4.7 The Indian Biologics Market
4.4.8 The Japanese Biologics Market
4.5.1 Market by Product: Monoclonal Antibodies (mABs), Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others
4.5.2 Market by Source: Microbial, Mammalian, and Others
4.5.3 Market by Disease Category: Oncology, Immunological Disorder, Cardiovascular Disorders, Hematological Disorders, and Others
4.5.4 Market by Manufacturing: Outsourced and In-house
4.5.5 Market by Distribution Channel: Online and Offline
4.5.6 Brazilian Biologics Market
7.1.1 Growth Opportunities for the Global Biologics Market by Product
7.1.2 Growth Opportunities for the Global Biologics Market by Source
7.1.3 Growth Opportunities for the Global Biologics Market by Disease Category
7.1.4 Growth Opportunities for the Global Biologics Market by Manufacturing
7.1.5 Growth Opportunities for the Global Biologics Market by Distribution Channel
7.1.6 Growth Opportunities for the Global Biologics Market by Region
Methodology
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in this market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Buy Now
Choose a license that fits your team. Instant PDF delivery.
Prices exclude taxes. Instant delivery. Custom licensing available on request.
